TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo^® and Yervoy^® in Mesothelin-Expressing Solid Tumors

TCR2 Therapeutics, Inc. announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo® and Yervoy® in its planned Phase II clinical trial in treatment refractory mesothelin-expressing solid tumors.